登上Cell主刊封面：浙江大学顾臻团队开发肥大细胞载药平台，让肿瘤“过敏”，增强癌症免疫治疗

Core Viewpoint - The recent study published in Cell journal explores the potential of sensitized mast cells as a targeted drug delivery system for cancer immunotherapy, redirecting the immune response typically associated with allergies to combat cancer [3][4][12]. Group 1: Research Overview - The study introduces an engineered mast cell platform that utilizes tumor-associated antigens as "allergens" to drive the accumulation of mast cells loaded with anti-tumor drugs, such as oncolytic viruses, to tumor sites [4][10]. - The research team developed an antigen-guided mast cell-mediated drug delivery system, demonstrating the innovative design through a cover image that symbolizes the interaction between antigens and mast cells [7]. Group 2: Mechanism and Findings - The study focuses on immunoglobulin E (IgE) sensitized mast cells (IgE-MC) for targeted delivery of oncolytic adenoviruses and local immune activation, showing significant potential in enhancing cancer treatment efficacy [8][10]. - IgE-MC can selectively target antigen-positive tumors, releasing oncolytic viruses and cytokines/chemokines upon antigen binding, thereby reversing immune suppression and activating anti-tumor immune responses [10][12]. Group 3: Safety and Efficacy - The infusion of IgE-MC is cleared within two weeks without disrupting mast cell homeostasis or inducing systemic allergic reactions, demonstrating a favorable safety profile [9]. - Compared to free oncolytic viruses, IgE-MC delivered oncolytic viruses showed reduced liver toxicity and no viral replication detected in normal tissues, indicating a safer therapeutic approach [9].